Overcoming PARP inhibitor resistance in ovarian cancer: what are the most promising strategies?
ConclusionAlthough the use of PARP inhibitors is a huge step forward, it is apparent that patients, both with and without BRCA-mutant ovarian cancer, will eventually become resistant to PARP inhibitors. Therefore, novel combination therapies may enhance PARP inhibitor efficacy and overcome resistance mechanisms.
Source: Archives of Gynecology and Obstetrics - Category: OBGYN Source Type: research
More News: Avastin | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Gastroschisis Repair | OBGYN | Ovarian Cancer | Ovaries